﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 11:32:43 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Amarantus Biosciences Announces the Release of Research Report by TomorrowsBlueChips.com</title><link>http://news.cision.com/amarantus-bioscience/r/amarantus-biosciences-announces-the-release-of-research-report-by-tomorrowsbluechips-com,c9283408</link><guid isPermaLink="false">cision1072825</guid><description><![CDATA[Sunnyvale, CA - Amarantus BioSciences Inc. (OTCBB: AMBS), a California-based biotechnology company focused on the development of a therapeutic protein known as MANF, announced today that TomorrowsBlueChips.com has profiled it in a 9-page research report that can be found directly on the web site under its Research section: http://tomorrowsbluechips.com/research/

The report’s analysis states, “Amarantus is now exposed to two global markets: Parkinson’s and Traumatic Brain Injury.” It adds that “Amarantus is interested in partnering opportunities for its product candidates that will allow]]></description><pubDate>Wed, 11 Jul 2012 12:00:00 GMT</pubDate></item><item><title>Amarantus BioSciences’ CEO Gerald Commissiong to Appear on the Big Biz Radio Show</title><link>http://news.cision.com/amarantus-bioscience/r/amarantus-biosciences--ceo-gerald-commissiong-to-appear-on-the-big-biz-radio-show,c9232726</link><guid isPermaLink="false">cision465784</guid><description><![CDATA[Sunnyvale, CA –Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Monday, March 19, 2012 at 1:20 PM EDT.  The live broadcast can be accessed via the show’s website:  http://bigbizshow.com/media/ . Amarantus’ previous four appearances on the Big Biz Show and other CEO interviews are available for viewing online at http://www.amarantus.com/investor-relations/videos.html .

The Big Biz Show is a nationwide radio broadcast]]></description><pubDate>Fri, 16 Mar 2012 14:03:03 GMT</pubDate></item><item><title>Amarantus BioSciences Releases New Video Interview with President and CEO Gerald Commissiong</title><link>http://news.cision.com/amarantus-bioscience/r/amarantus-biosciences-releases-new-video-interview-with-president-and-ceo-gerald-commissiong,c9204767</link><guid isPermaLink="false">cision436669</guid><description><![CDATA[Sunnyvale, CA, Jan. 6. 2012--Amarantus BioSciences Inc (http://www.amarantus.com/). (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Recently, the biotech company released a video interview (http://snnwire.com/Media/index.php/show/gerald_commissiong_amarantus_biosciences_niba_las_vegas_2011?id=0_0bctlct6) with its CEO, Gerald Commissiong that covers its development of MANF. Unlike Insmed Inc. (NASDAQ: INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the]]></description><pubDate>Fri, 06 Jan 2012 14:00:00 GMT</pubDate></item><item><title>New Webcast Interview with President and CEO Gerald Commissiong (OTCBB: AMBS) Now Available at TheGreenBaron.com</title><link>http://news.cision.com/amarantus-bioscience/r/new-webcast-interview-with-president-and-ceo-gerald-commissiong--otcbb--ambs--now-available-at-thegr,c9192144</link><guid isPermaLink="false">cision423622</guid><description><![CDATA[SUNNYVALE, CA – November 29, 2011 – Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, announces today that its President and CEO Gerald Commissiong has conducted an exclusive new audio-taped webcast interview so that AMBS shareholders and the investment community can learn more about the Company’s recent developments and growth plans. Unrestricted access to the webcast is now available on the “Webcasts” page at www.TheGreenBaron.com. Investors who wish to receive The Green Baron Report for free can]]></description><pubDate>Tue, 29 Nov 2011 11:00:00 GMT</pubDate></item><item><title>Amarantus Bioscience, a Promising Biotech Company in Development</title><link>http://news.cision.com/amarantus-bioscience/r/amarantus-bioscience--a-promising-biotech-company-in-development,c9186824</link><guid isPermaLink="false">cision417271</guid><description><![CDATA[Miami, FL - Founded in California in 2008, Amarantus Biosciences, Inc. (http://www.amarantus.com/) (OTCBB: AMBS) is now poised to take the biotech world by storm with their proprietary new technology. It’s called Mesencephalic-Astrocyte-derived Neurotrophic Factor, or MANF (http://www.amarantus.com/investor-relations/scientific-publications.html), for short. Discovered by combining research conducted at the National Institutes of Health throughout the 1990s, this highly potent protein treatment for diseases caused by cell death (apoptosis) is currently in pre-clinical development. Their]]></description><pubDate>Mon, 14 Nov 2011 15:48:42 GMT</pubDate></item></channel></rss>